FDA — authorised 20 March 2018
- Marketing authorisation holder: SUN PHARMA GLOBAL
- Status: approved
🇺🇸 Sunpg 1622 in United States
FDA authorised Sunpg 1622 on 20 March 2018
Marketing authorisations
FDA — authorised 19 December 2022
- Application: BLA761067
- Marketing authorisation holder: SUN PHARMA GLOBAL
- Indication: Efficacy
- Status: approved
Sunpg 1622 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Sunpg 1622 approved in United States?
Yes. FDA authorised it on 20 March 2018; FDA authorised it on 19 December 2022.
Who is the marketing authorisation holder for Sunpg 1622 in United States?
SUN PHARMA GLOBAL holds the US marketing authorisation.